{"schema_version":"1.0","type":"article","title":"2026 ASCO：生存期翻倍、體內 CAR-T 破局，腫瘤治療正在換一個時代","url":"https://drugnews.com.tw/articles/2026-06-15-2026-asco-car-t.html","markdown_url":"https://drugnews.com.tw/articles/2026-06-15-2026-asco-car-t.md","lang":"zh-Hant","date":"2026-06-15","publish_at":"2026-06-15T10:35:00+08:00","updated_at":"2026-06-15","category":"醫學大會","topic":"醫學大會","tags":["醫學大會","免費文章","ASCO","腫瘤治療","CAR-T","RAS","ADC","臨床數據","生技投資","製藥巨頭"],"summary":"2026 年美國臨床腫瘤學會年會，也就是 ASCO，最該被記住的贏家，並不是任何一家藥廠，而是癌症患者。","key_points":[],"facts":[],"sections":["01｜Revolution Medicines：胰臟癌裡的一記滿貫全壘打","02｜Merck：Keytruda 王權仍在，但後專利懸崖已經不能只靠 Keytruda","03｜PD-(L)1／VEGF 雙抗：中國資料很漂亮，但全球化才是真正大考","04｜Lilly／Kelonia：體內 CAR-T 讓細胞治療看見另一種未來","05｜Pfizer：看似低調，其實正在重新堆疊 ADC 版圖","06｜Immuneering：資料不差，但市場情緒被 Revolution 抬高了標準","07｜2026 ASCO 的真正訊號：腫瘤治療正在進入多平台並行時代","08｜台灣 ASCO 後如何看待？看資料品質與平台能力","結語｜2026 ASCO 不是誰贏了，而是腫瘤治療的戰場變大了"],"references":[{"title":"[1] ASCO","source":"Abstracts and presentations:","date":"","url":"https://www.asco.org/abstracts-presentations/267303"},{"title":"[2] Revolution Medicines","source":"Investor relations and clinical updates:","date":"","url":"https://ir.revmed.com/"},{"title":"[3] BioNTech","source":"Oncology pipeline and company news:","date":"","url":"https://investors.biontech.de/"},{"title":"[4] Kelonia Therapeutics","source":"Company news and presentations:","date":"","url":"https://keloniatx.com/news/"},{"title":"[5] Reuters","source":"Healthcare and pharmaceutical industry coverage:","date":"","url":"https://www.reuters.com/business/healthcare-pharmaceuticals/"}],"images":[{"alt":"Facebook 原圖：2026 ASCO：生存期翻倍、體內 CAR-T 破局，腫瘤治療正在換一個時代（圖 1）","url":"https://drugnews.com.tw/assets/articles/2026-asco-car-t/facebook-01.jpg"},{"alt":"Facebook 原圖：2026 ASCO：生存期翻倍、體內 CAR-T 破局，腫瘤治療正在換一個時代（圖 2）","url":"https://drugnews.com.tw/assets/articles/2026-asco-car-t/facebook-02.jpg"},{"alt":"Facebook 原圖：2026 ASCO：生存期翻倍、體內 CAR-T 破局，腫瘤治療正在換一個時代（圖 3）","url":"https://drugnews.com.tw/assets/articles/2026-asco-car-t/facebook-03.jpg"},{"alt":"Facebook 原圖：2026 ASCO：生存期翻倍、體內 CAR-T 破局，腫瘤治療正在換一個時代（圖 4）","url":"https://drugnews.com.tw/assets/articles/2026-asco-car-t/facebook-04.jpg"}],"cover_image":"https://drugnews.com.tw/assets/articles/2026-asco-car-t/cover-generated.png","publisher":{"name":"Drugnews｜藥時事","url":"https://drugnews.com.tw/","profile":"https://drugnews.com.tw/brand-profile.json"},"citation":"Drugnews｜藥時事（2026-06-15）。2026 ASCO：生存期翻倍、體內 CAR-T 破局，腫瘤治療正在換一個時代。https://drugnews.com.tw/articles/2026-06-15-2026-asco-car-t.html","disclaimer":"本文僅供產業研究與知識分享，不構成投資、醫療、募資或個股建議。","translations":{"en":"2026-06-15-2026-asco-car-t-en.html"},"relationship":"independent_editorial","disclosure_url":"https://drugnews.com.tw/policy/"}